Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis

BACKGROUND: After the approval of pazopanib for the treatment of soft tissue sarcoma (STS), pneumothorax was reported as an unexpected adverse event during pazopanib treatment. The incidence and risk factors of pneumothorax during pazopanib treatment for STSs have not been established yet. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Kenji, Motoi, Noriko, Tomomatsu, Junichi, Gokita, Tabu, Ae, Keisuke, Tanizawa, Taisuke, Matsumoto, Seiichi, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035441/
https://www.ncbi.nlm.nih.gov/pubmed/27663525
http://dx.doi.org/10.1186/s12885-016-2786-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035441/
https://www.ncbi.nlm.nih.gov/pubmed/27663525
http://dx.doi.org/10.1186/s12885-016-2786-z

Ejemplares similares